Bladder cancer: why blood in the urine matters and why there is no screening for it
Smoking is the leading modifiable cause, and the most common presenting sign is blood in the urine. There is no recommended screening test, which makes that sign the thing to act on.
Bladder cancer is common — the fourth most common malignancy in men, and a frequent one in women — yet it gets far less public attention than breast, prostate or colorectal cancer [s1]. It also sits in an unusual position: there is no recommended screening test for it, and its most common warning sign is one people are inclined to ignore or explain away. That combination makes understanding the sign unusually important.
What raises the risk
The established contributors are advanced age, male sex, and cigarette smoking [s1]. Smoking is the one that can be changed, and it is a major driver — tobacco carcinogens are concentrated and excreted in the urine, bringing them into prolonged contact with the bladder lining. Smoking is one of the established modifiable causes of cancer generally [s3], and bladder cancer is among the cancers where that link is strongest. As with other smoking-related cancers, the most effective form of prevention is not a test but not smoking.
The sign that matters: blood in the urine
Bladder tumours characteristically present with blood in the urine — either gross haematuria, visible to the eye, or microscopic haematuria, detected on a urine test [s1]. When haematuria is found, it is evaluated with cystoscopy, a camera passed into the bladder, and imaging of the upper urinary tract, with the intensity of the workup depending on how much blood is present and the person's risk of malignancy [s1].
The reason this deserves emphasis is that visible blood in the urine is easy to dismiss — it is often painless, it may appear once and vanish, and it has many benign causes such as infection. But it is also the classic presenting sign of bladder cancer, which is why it is investigated rather than watched. The appropriate response to blood in the urine is not alarm and not self-diagnosis; it is medical assessment, because a clinician can distinguish the common harmless causes from the ones that need attention. Most haematuria is not cancer, but it is not something to wait out.
Why there is no screening programme
If blood in the urine is a warning sign, why not screen everyone's urine for it routinely? The US Preventive Services Task Force examined that question and concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults — an "I statement" [s2]. As with skin cancer, that is not a verdict that screening is harmful, but a finding that the trials needed to show whether screening asymptomatic people does more good than harm have not been done. In the absence of that evidence, there is no routine population screening, which is precisely why recognising and acting on symptoms carries the weight that a screening test otherwise would.
After diagnosis
Treatment depends heavily on how deeply the cancer has invaded the bladder wall. Non-muscle-invasive tumours are typically managed by endoscopic removal followed, depending on risk, by therapy instilled directly into the bladder — most commonly the immunotherapy BCG — and long-term surveillance [s1]. Muscle-invasive disease calls for more aggressive treatment, either removal of the bladder with urinary diversion or a bladder-preserving combination of maximal resection, chemotherapy and radiation [s1]. These are specialist decisions, and the details for any individual belong with the treating team.
What this means for a reader
The practical takeaways are narrow and concrete. Not smoking is the main modifiable way to lower bladder cancer risk [s1][s3]. There is no routine screening test to request [s2], so the most useful thing a person can do is treat blood in the urine — visible or flagged on a test — as a reason to see a clinician promptly, rather than assuming it is nothing. That is general information about a warning sign, not a statement that the sign means cancer; only assessment can determine the cause.
Sources
- [s1] Bladder Cancer: A Review, JAMA, 2020-11-01
- [s2] Screening for Bladder Cancer: USPSTF Recommendation Statement, Annals of Internal Medicine, 2011-08-16
- [s3] Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, CA: A Cancer Journal for Clinicians, 2017-11-21
Sources
- Bladder Cancer: A Review — JAMA , November 1, 2020
- Screening for Bladder Cancer: U.S. Preventive Services Task Force Recommendation Statement — Annals of Internal Medicine , August 16, 2011
- Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States — CA - A Cancer Journal for Clinicians , November 21, 2017
Why there is no routine screening for pancreatic cancer, and what raises the risk
The disease is lethal largely because it is found late. That is also why guidelines recommend against screening the general public — the evidence says it would do more harm than good.
Who lung-cancer screening is actually for, and what the trials show it does
Two large randomised trials found low-dose CT screening cut lung-cancer deaths in heavy smokers. The eligibility rules are narrow, and the reason is written into the evidence.
Colorectal screening now starts at 45. Here is what the tests are and why the age dropped
A stool test at home and a colonoscopy are both recommended options with different trade-offs. The starting age fell to 45 because the disease is rising in younger adults.
Skin cancer: what the evidence says about screening and spotting melanoma
Most skin cancers rarely kill; melanoma, about 1 percent of them, causes most of the deaths. There is no proven benefit from routine whole-body screening — which puts the focus on changing moles.